EGFR and non-small cell lung carcinoma: ICIs did not improve OS vs. docetaxel in NSCLC patients with EGFR mutations (HR = 1.05 95% CI:0.70–1.55, p < 0.81) vs. WT (HR = 0.66, 95% CI:0.58–0.76, p < 0.0001)